Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Charles River Labs ( (CRL) ).
On January 8, 2026, Charles River Laboratories announced a leadership transition under which long-time Chairman, President and Chief Executive Officer James C. Foster will step down as CEO and Chair of the Board effective May 5, 2026, while remaining on the board as a non-executive director. Chief Operating Officer Birgit Girshick will become Chief Executive Officer on that date and has been nominated to join the board at the 2026 annual shareholders’ meeting, with Lead Independent Director Martin Mackay slated to become Chair of the Board and the board expanding from 11 to 12 members with consent from Elliott-affiliated shareholders, reflecting a carefully structured change in governance and continuity of leadership. In connection with her promotion, Girshick’s compensation package will be significantly enhanced, including a higher base salary, an increased target annual cash incentive, and a substantial equity grant largely in performance share units, along with change-in-control protections and retirement treatment for certain equity awards, underscoring the board’s commitment to aligning her incentives with long-term performance. The compensation committee also approved a two-year cliff-vesting restricted stock unit grant valued at $3 million for Foster in recognition of his service as CEO during part of fiscal 2026, after which he is expected to receive compensation consistent with other non-executive directors.
The most recent analyst rating on (CRL) stock is a Buy with a $215.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.
Spark’s Take on CRL Stock
According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.
Charles River Labs’ overall stock score is primarily impacted by its financial performance challenges, including declining revenue and profitability. Technical analysis shows positive momentum, but valuation concerns with a negative P/E ratio weigh heavily. The earnings call provides a mixed outlook, with strategic initiatives offering some optimism amid operational challenges.
To see Spark’s full report on CRL stock, click here.
More about Charles River Labs
Charles River Laboratories International, Inc. operates in the life sciences and pharmaceutical services industry, providing research models and related services that support drug discovery and development for biopharmaceutical companies and other research organizations.
Average Trading Volume: 907,408
Technical Sentiment Signal: Buy
Current Market Cap: $10.67B
For an in-depth examination of CRL stock, go to TipRanks’ Overview page.